A proposed bill to classify Xylazine as a controlled substance in California has sparked intense discussions among lawmakers and advocates during a recent Assembly Public Safety Committee meeting. Known colloquially as the "zombie drug," Xylazine has been linked to a troubling rise in overdose deaths, particularly when mixed with fentanyl. The bill aims to schedule Xylazine as a Schedule 3 drug, which would impose restrictions on its availability while still allowing its use in veterinary medicine.

Senator Ashby, who presented the bill, emphasized the urgency of addressing the growing prevalence of Xylazine in the state. "Xylazine has tripled the effect of deaths in our region," she stated, highlighting the drug's dangerous effects, which can leave users incapacitated and with severe wounds. The senator noted that while the bill is not a panacea for the opioid crisis, it is a necessary step in a broader strategy to combat drug-related issues in California.

Supporters of the bill, including veterinary professionals and advocates for drug policy reform, argue that regulating Xylazine is crucial for public safety. Dr. Grant Miller from the California Veterinary Medical Association explained the drug's legitimate use in large animals, asserting that veterinarians can manage its distribution responsibly. Marika Cole, a mother who lost her son to drug-related issues, echoed the need for restrictions, stating, "The chaos on the streets has to stop."

However, the bill faced significant opposition from various advocacy groups, including the ACLU and the Drug Policy Alliance. Critics argue that criminalizing Xylazine will not effectively reduce its presence in the illicit drug supply and may exacerbate the challenges faced by individuals struggling with addiction. They warn that similar measures in other states have led to increased overdose fatalities rather than a decrease.

As the committee deliberated, some members expressed concerns about the potential for increased criminalization of drug users, particularly in marginalized communities. The debate highlighted the ongoing struggle to find effective solutions to the opioid crisis without resorting to punitive measures.

The committee's decision on the bill remains pending, but the discussions underscore the complexities of addressing drug-related issues in California. Advocates on both sides agree that a multifaceted approach is necessary, combining regulation with support services to truly make a difference in the lives of those affected by substance use disorders.